Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Many US employers plan to pare health benefits as weight-loss spending soars - Nation and World News | Hawaii Tribune-Herald ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS ) securities between April 29, 2025 and June 23, 2025, both dates ...

Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...